Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Inspirna, Inc.
H. Lee Moffitt Cancer Center and Research Institute
ETOP IBCSG Partners Foundation
Xencor, Inc.
Lung Cancer Group Cologne
Incyte Corporation
Bristol-Myers Squibb
Bristol-Myers Squibb
University Hospital Southampton NHS Foundation Trust